Insider Buy/Sell Details for the Biotechnology Industry — Last 3 Months
Ratio0.1:1
Daily Buy & Sell Volume
Transactions (3460)
UNITED THERAPEUTICS Corp (UTHR)
ROTHBLATT MARTINE A — Director
Shares
1,875
Price
$558.90
Total Value
$1.05M
Shares Held After
45,279
% of Holdings
4.0%
UNITED THERAPEUTICS Corp (UTHR)
ROTHBLATT MARTINE A — Director
Shares
1,096
Price
$557.78
Total Value
$611.32K
Shares Held After
47,154
% of Holdings
2.3%
UNITED THERAPEUTICS Corp (UTHR)
ROTHBLATT MARTINE A — Director
Shares
726
Price
$556.55
Total Value
$404.06K
Shares Held After
48,250
% of Holdings
1.5%
UNITED THERAPEUTICS Corp (UTHR)
ROTHBLATT MARTINE A — Director
Shares
596
Price
$555.50
Total Value
$331.08K
Shares Held After
48,976
% of Holdings
1.2%
UNITED THERAPEUTICS Corp (UTHR)
ROTHBLATT MARTINE A — Director
Shares
241
Price
$554.36
Total Value
$133.60K
Shares Held After
49,572
% of Holdings
0.5%
UNITED THERAPEUTICS Corp (UTHR)
ROTHBLATT MARTINE A — Director
Shares
200
Price
$553.12
Total Value
$110.62K
Shares Held After
49,813
% of Holdings
0.4%
Theravance Biopharma, Inc. (TBPH)
Samaha Eli — 10% Owner
Shares
5,564
Price
$17.17
Total Value
$95.54K
Shares Held After
9,167,489
% of Holdings
0.1%
ProQR Therapeutics N.V. (PRQR)
de Boer Daniel Anton — Director
Shares
150,000
Price
$1.59
Total Value
$238.50K
Shares Held After
150,000
% of Holdings
100.0%
MeiraGTx Holdings plc (MGTX)
Naylor Stuart — CHIEF SCI OFCR, OPHTHALMOLOGY
Shares
25,112
Price
$14.90
Total Value
$374.17K
Shares Held After
640,846
% of Holdings
3.8%
MeiraGTx Holdings plc (MGTX)
Naylor Stuart — CHIEF SCI OFCR, OPHTHALMOLOGY
Shares
2,547
Price
$13.86
Total Value
$35.30K
Shares Held After
665,958
% of Holdings
0.4%
Neurogene Inc. (NGNE)
Cvijic Christine Mikail — Director
Shares
4,200
Price
$36.13
Total Value
$151.76K
Shares Held After
84,040
% of Holdings
4.8%
Kymera Therapeutics, Inc. (KYMR)
Mainolfi Nello — Director
Shares
50,000
Price
$119.00
Total Value
$5.95M
Shares Held After
666,568
% of Holdings
7.0%
Immunome Inc. (IMNM)
Barchas Isaac — Director
Shares
16,906
Price
$24.20
Total Value
$409.13K
Shares Held After
108,504
% of Holdings
13.5%
Eton Pharmaceuticals, Inc. (ETON)
Opaleye Management Inc. — 10% Owner
Shares
6,685
Price
$38.37
Total Value
$256.52K
Shares Held After
53,315
% of Holdings
11.1%
Eton Pharmaceuticals, Inc. (ETON)
Opaleye Management Inc. — 10% Owner
Shares
20,000
Price
$38.37
Total Value
$767.46K
Shares Held After
2,680,000
% of Holdings
0.7%
CYTOKINETICS INC (CYTK)
Malik Fady Ibraham — EVP Research & Development
Shares
3,500
Price
$86.62
Total Value
$303.17K
Shares Held After
153,902
% of Holdings
2.2%
Xeris Biopharma Holdings, Inc. (XERS)
Pieper Steven — Chief Financial Officer
Shares
27,600
Price
$8.52
Total Value
$235.28K
Shares Held After
1,366,053
% of Holdings
2.0%
PUMA BIOTECHNOLOGY, INC. (PBYI)
HUNT DOUGLAS M — The Reporting Person is the Senior Vice President of Regulatory Affairs of the Issuer.
Shares
8,460
Price
$8.26
Total Value
$69.90K
Shares Held After
196,841
% of Holdings
4.1%
PUMA BIOTECHNOLOGY, INC. (PBYI)
NOUGUES MAXIMO F — Chief Financial Officer
Shares
9,386
Price
$8.26
Total Value
$77.56K
Shares Held After
230,637
% of Holdings
3.9%
Boundless Bio, Inc. (BOLD)
TANG KEVIN — 10% Owner
Shares
27,062
Price
$2.49
Total Value
$67.38K
Shares Held After
2,668,370
% of Holdings
1.0%
PUMA BIOTECHNOLOGY, INC. (PBYI)
AUERBACH ALAN H — Director
Shares
44,058
Price
$8.26
Total Value
$364.05K
Shares Held After
7,261,671
% of Holdings
0.6%
PALISADE BIO, INC. (PALI)
Baltera Robert Jr. — Director
Shares
20,000
Price
$2.05
Total Value
$41.04K
Shares Held After
386,904
% of Holdings
5.2%
Werewolf Therapeutics, Inc. (HOWL)
EVNIN LUKE — Director
Shares
35,770
Price
$0.32
Total Value
$11.45K
Shares Held After
107,429
% of Holdings
25.0%
Dyne Therapeutics, Inc. (DYN)
Rhodes Jason P — Director
Shares
100,019
Price
$22.79
Total Value
$2.28M
Shares Held After
875,912
% of Holdings
10.2%
Dyne Therapeutics, Inc. (DYN)
Rhodes Jason P — Director
Shares
127,182
Price
$22.79
Total Value
$2.90M
Shares Held After
1,217,537
% of Holdings
9.5%
Dyne Therapeutics, Inc. (DYN)
Rhodes Jason P — Director
Shares
253,039
Price
$22.79
Total Value
$5.77M
Shares Held After
4,223,448
% of Holdings
5.7%
Relay Therapeutics, Inc. (RLAY)
Catinazzo Thomas — Chief Financial Officer
Shares
17,717
Price
$18.69
Total Value
$331.13K
Shares Held After
159,744
% of Holdings
10.0%
Enliven Therapeutics, Inc. (ELVN)
Kunkel Lori Anne — Director
Shares
5,889
Price
$50.84
Total Value
$299.42K
Shares Held After
41,884
% of Holdings
12.3%
Enliven Therapeutics, Inc. (ELVN)
Kunkel Lori Anne — Director
Shares
4,111
Price
$49.98
Total Value
$205.48K
Shares Held After
47,773
% of Holdings
7.9%
PTC THERAPEUTICS, INC. (PTCT)
Almstead Neil Gregory — CHIEF TECHNICAL OPS OFFICER
Shares
2,474
Price
$87.03
Total Value
$215.31K
Shares Held After
60,299
% of Holdings
3.9%
PTC THERAPEUTICS, INC. (PTCT)
Almstead Neil Gregory — CHIEF TECHNICAL OPS OFFICER
Shares
10,090
Price
$86.32
Total Value
$870.97K
Shares Held After
60,299
% of Holdings
14.3%
PTC THERAPEUTICS, INC. (PTCT)
Almstead Neil Gregory — CHIEF TECHNICAL OPS OFFICER
Shares
8,786
Price
$85.35
Total Value
$749.89K
Shares Held After
70,389
% of Holdings
11.1%
PTC THERAPEUTICS, INC. (PTCT)
Almstead Neil Gregory — CHIEF TECHNICAL OPS OFFICER
Shares
385
Price
$86.34
Total Value
$33.24K
Shares Held After
60,299
% of Holdings
0.6%
PTC THERAPEUTICS, INC. (PTCT)
Almstead Neil Gregory — CHIEF TECHNICAL OPS OFFICER
Shares
426
Price
$85.28
Total Value
$36.33K
Shares Held After
60,684
% of Holdings
0.7%
PTC THERAPEUTICS, INC. (PTCT)
Boulding Mark Elliott — EXEC. VP AND CLO
Shares
745
Price
$86.38
Total Value
$64.35K
Shares Held After
105,272
% of Holdings
0.7%
PTC THERAPEUTICS, INC. (PTCT)
Boulding Mark Elliott — EXEC. VP AND CLO
Shares
645
Price
$85.84
Total Value
$55.37K
Shares Held After
106,017
% of Holdings
0.6%
PTC THERAPEUTICS, INC. (PTCT)
Boulding Mark Elliott — EXEC. VP AND CLO
Shares
1,036
Price
$84.41
Total Value
$87.45K
Shares Held After
106,662
% of Holdings
1.0%
PTC THERAPEUTICS, INC. (PTCT)
Boulding Mark Elliott — EXEC. VP AND CLO
Shares
387
Price
$83.10
Total Value
$32.16K
Shares Held After
107,698
% of Holdings
0.4%
PTC THERAPEUTICS, INC. (PTCT)
Boulding Mark Elliott — EXEC. VP AND CLO
Shares
601
Price
$86.38
Total Value
$51.91K
Shares Held After
105,272
% of Holdings
0.6%
PTC THERAPEUTICS, INC. (PTCT)
Boulding Mark Elliott — EXEC. VP AND CLO
Shares
519
Price
$85.84
Total Value
$44.55K
Shares Held After
105,873
% of Holdings
0.5%
PTC THERAPEUTICS, INC. (PTCT)
Boulding Mark Elliott — EXEC. VP AND CLO
Shares
833
Price
$84.41
Total Value
$70.31K
Shares Held After
106,392
% of Holdings
0.8%
PTC THERAPEUTICS, INC. (PTCT)
Boulding Mark Elliott — EXEC. VP AND CLO
Shares
313
Price
$83.10
Total Value
$26.01K
Shares Held After
107,225
% of Holdings
0.3%
Relay Therapeutics, Inc. (RLAY)
Bergstrom Donald A — President, R&D
Shares
8,660
Price
$18.71
Total Value
$162.03K
Shares Held After
409,897
% of Holdings
2.1%
Mirum Pharmaceuticals, Inc. (MIRM)
Peetz Christopher — Director
Shares
1,710
Price
$124.79
Total Value
$213.39K
Shares Held After
194,309
% of Holdings
0.9%
Mirum Pharmaceuticals, Inc. (MIRM)
Peetz Christopher — Director
Shares
1,975
Price
$123.74
Total Value
$244.39K
Shares Held After
196,019
% of Holdings
1.0%
Mirum Pharmaceuticals, Inc. (MIRM)
Peetz Christopher — Director
Shares
4,181
Price
$122.34
Total Value
$511.50K
Shares Held After
197,994
% of Holdings
2.1%
Mirum Pharmaceuticals, Inc. (MIRM)
Peetz Christopher — Director
Shares
12,134
Price
$121.65
Total Value
$1.48M
Shares Held After
202,175
% of Holdings
5.7%
Mirum Pharmaceuticals, Inc. (MIRM)
BJERKHOLT ERIC — CHIEF FINANCIAL OFFICER
Shares
300
Price
$124.94
Total Value
$37.48K
Shares Held After
42,181
% of Holdings
0.7%
Mirum Pharmaceuticals, Inc. (MIRM)
BJERKHOLT ERIC — CHIEF FINANCIAL OFFICER
Shares
528
Price
$123.84
Total Value
$65.39K
Shares Held After
42,481
% of Holdings
1.2%
Mirum Pharmaceuticals, Inc. (MIRM)
BJERKHOLT ERIC — CHIEF FINANCIAL OFFICER
Shares
1,048
Price
$122.43
Total Value
$128.31K
Shares Held After
43,009
% of Holdings
2.4%
Showing 901–950 of 3460 transactions (page 19 of 70)